David Pyott - Biomarin Pharmaceutical Independent Director

BMRN Stock  USD 88.61  0.87  0.99%   

Director

Mr. David E. I. Pyott, M.D. is an Independent Director of the Company since January 2016 since 2016.
Age 63
Tenure 8 years
Professional MarksMBA
Phone415 506 6700
Webhttps://www.biomarin.com
Pyott joined our Board in January 2016. From 1998 to March 2015, Dr. Pyott served as Chief Executive Officer of Allergan, Inc., a global pharmaceutical company. Prior to Allergan, Dr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerlandbased Novartis AG. Dr. Pyott is Lead Director and a member of the board of Avery Dennison Corporationrationrationration, a public global labeling and packaging materials company, serves on the board of Alnylam Pharmaceuticals, Inc., a public biotechnology company and is a member of the Supervisory Board of Royal Philips in the Netherlands, a public diversified health and technology company. Dr. Pyott serves as Chairman of Bioniz Therapeutics, Inc., a private biotechnology company, and serves on the board of Rani Therapeutics, LLC, a private biotechnology company

Biomarin Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.0163 % which means that it generated a profit of $0.0163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0351 %, meaning that it created $0.0351 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 1.13 B in liabilities with Debt to Equity (D/E) ratio of 0.24, which may suggest the company is not taking enough advantage from borrowing. Biomarin Pharmaceutical has a current ratio of 5.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Biomarin Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Biomarin Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biomarin Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biomarin to invest in growth at high rates of return. When we think about Biomarin Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Bradley GaboschOld Dominion Freight
66
Jonathan MarinerTyson Foods
66
Justin KnowlesEagle Bulk Shipping
49
David McDonaldMarfrig Global Foods
N/A
Joao CastroNevesKraft Heinz Co
N/A
Tracy CoolKraft Heinz Co
32
John PopeKraft Heinz Co
68
John CongdonOld Dominion Freight
61
Robert ThurberTyson Foods
72
Cecil ConleeNational Beverage Corp
80
Leo SuggsOld Dominion Freight
78
Jonathan DowsettEagle Bulk Shipping
N/A
Cheryl MillerTyson Foods
48
John KasardaOld Dominion Freight
72
Mackey McDonaldKraft Heinz Co
69
Feroz DewanKraft Heinz Co
40
Fabio VasconcellosMarfrig Global Foods
N/A
Mike BeebeTyson Foods
74
Ernesto LozardoMarfrig Global Foods
N/A
Casey ShanleyEagle Bulk Shipping
N/A
Barbara TysonTyson Foods
71
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company was incorporated in 1996 and is headquartered in San Rafael, California. Biomarin Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3045 people. Biomarin Pharmaceutical (BMRN) is traded on NASDAQ Exchange in USA. It is located in 770 Lindaro Street, San Rafael, CA, United States, 94901 and employs 3,401 people. Biomarin Pharmaceutical is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Biomarin Pharmaceutical Leadership Team

Elected by the shareholders, the Biomarin Pharmaceutical's board of directors comprises two types of representatives: Biomarin Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomarin. The board's role is to monitor Biomarin Pharmaceutical's management team and ensure that shareholders' interests are well served. Biomarin Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomarin Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Elaine Heron, Independent Director
Dennis Slamon, Director
Henry Fuchs, Executive Vice President and Chief Medical Officer
George Davis, Chief VP
Robert Hombach, Independent Director
Philip Scalzo, VP Officer
JeanJacques Bienaime, Chairman of the Board, CEO
Jeff Ajer, Executive Vice President Chief Commercial Officer
Richard Meier, Independent Director
Willard Dere, Director
Amy Wireman, Executive Officer
Jeffrey Ajer, Executive Officer
Eric Davis, Sr. VP, General Counsel and Secretary
Pierre Lapalme, Independent Chairman of the Board
Robert Baffi, Executive VP of Technical Operations
Richard Ranieri, Senior Vice President - Human Resources and Corporate Affairs
Elizabeth Anderson, Independent Director
Traci McCarty, Group Relations
Humaira Serajuddin, Senior Officer
Brian Mueller, Chief Accounting Officer, Group VP and Controller
Liz Anderson, Director
Erin Burkhart, Group Officer
Bryan Lawlis, Independent Director
Greg Guyer, CTO Operations
Daniel Spiegelman, CFO, Executive Vice President
Kevin Eggan, Chief Development
Kathryn Falberg, Director
Alexander Hardy, CEO President
MBA MBA, Chairman CEO
Alan Lewis, Independent Director
David Pyott, Independent Director
Michael Grey, Independent Director

Biomarin Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomarin Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biomarin Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biomarin Pharmaceutical's short interest history, or implied volatility extrapolated from Biomarin Pharmaceutical options trading.

Pair Trading with Biomarin Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biomarin Stock

  0.67MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr
  0.87MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Biomarin Stock

  0.9DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.81MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.78EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.75MDWD Mediwound Downward RallyPairCorr
  0.69MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Biomarin Stock analysis

When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Money Managers
Screen money managers from public funds and ETFs managed around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.